{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:38:04Z","timestamp":1787611084193,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ab.2018.12.014","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T20:51:15Z","timestamp":1545339075000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An LC\/MS based method to quantify DNA adduct in tumor and organ tissues"],"prefix":"10.1016","volume":"568","author":[{"given":"Chao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrand","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo","family":"Abdul-Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Abu-Yousif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2018.12.014_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ab.2018.12.014_bib2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates: A new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ab.2018.12.014_bib3","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","article-title":"Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates","volume":"32","author":"Kamath","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ab.2018.12.014_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10928-013-9344-y","article-title":"Target-mediated drug disposition model and its approximations for antibody-drug conjugates","volume":"41","author":"Gibiansky","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ab.2018.12.014_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/bdd.1957","article-title":"Challenges and advances in the assessment of the disposition of antibody-drug conjugates","volume":"37","author":"Kamath","year":"2016","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ab.2018.12.014_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4155\/bio.13.68","article-title":"Bioanalysis special focus issue on antibody-drug conjugates","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4155\/bio.15.106","article-title":"Bioanalysis of antibody-drug conjugates","volume":"7","author":"Gorovits","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4155\/bio.13.38","article-title":"Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper","volume":"5","author":"Gorovits","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4155\/bio.13.78","article-title":"Key bioanalytical measurements for antibody-drug conjugate development: PK\/PD modelers' perspective","volume":"5","author":"Shah","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1124\/dmd.116.070631","article-title":"Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates","volume":"44","author":"Zhang","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ab.2018.12.014_bib12","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ab.2018.12.014_bib13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.109.155549","article-title":"The pharmacologic basis for antibody-auristatin conjugate activity","volume":"330","author":"Alley","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ab.2018.12.014_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-11-0727","article-title":"The effect of different linkers on target cell catabolism and pharmacokinetics\/pharmacodynamics of trastuzumab maytansinoid conjugates","volume":"11","author":"Erickson","year":"2012","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ab.2018.12.014_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1208\/s12248-014-9576-9","article-title":"A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate","volume":"16","author":"Shah","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ab.2018.12.014_bib16","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1021\/acs.bioconjchem.5b00205","article-title":"Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor\/Tissue Distribution in Mice","volume":"26","author":"Leal","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ab.2018.12.014_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ab.2018.12.014_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","article-title":"Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ab.2018.12.014_bib19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-014-2561-2","article-title":"Mechanistic pharmacokinetic\/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates","volume":"74","author":"Wada","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ab.2018.12.014_bib20","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4155\/bio.12.234","article-title":"Tissue bioanalysis of biotherapeutics and drug targets to support PK\/PD","volume":"4","author":"Neubert","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody-drug conjugates","volume":"255","author":"Kovtun","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ab.2018.12.014_bib22","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ab.2018.12.014_bib23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4155\/bio.13.57","article-title":"Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications","volume":"5","author":"Thevanayagam","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2018.12.014_bib24","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ab.2018.12.014_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ab.2012.11.001","article-title":"Optimized enzymatic hydrolysis of DNA for LC-MS\/MS analyses of adducts of 1-methoxy-3-indolylmethyl glucosinolate and methyleugenol","volume":"434","author":"Schumacher","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2018.12.014_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-0940","article-title":"A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)","author":"Miller","year":"2018","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ab.2018.12.014_bib27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1039\/c0ob00762e","article-title":"Observation of the reversibility of a covalent pyrrolobenzodiazepine (PBD) DNA adduct by HPLC\/MS and CD spectroscopy","volume":"9","author":"Rahman","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ab.2018.12.014_bib28","article-title":"Intratumoral Payload Concentration Correlates with the Activity of Antibody- Drug Conjugates","author":"Zhang","year":"2018","journal-title":"Mol. Canc. Therapeut."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269718311370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269718311370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:24:37Z","timestamp":1757712277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269718311370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"alternative-id":["S0003269718311370"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2018.12.014","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An LC\/MS based method to quantify DNA adduct in tumor and organ tissues","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}